Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$221.50
-0.6%
$211.94
$189.44
$319.76
$32.25B-0.011.36 million shs655,151 shs
Cerner Co. stock logo
CERN
Cerner
$94.92
$94.92
$69.08
$95.40
$27.92B0.774.00 million shs1,320 shs
ResMed Inc. stock logo
RMD
ResMed
$213.82
-1.4%
$194.32
$132.24
$237.26
$31.41B0.641.34 million shs635,286 shs
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$364.19
-0.4%
$378.61
$310.42
$415.73
$26.53B1.05493,814 shs488,302 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.56%+1.83%+9.90%-8.08%-29.29%
Cerner Co. stock logo
CERN
Cerner
0.00%0.00%0.00%0.00%0.00%
ResMed Inc. stock logo
RMD
ResMed
-1.44%-1.46%+10.31%+15.81%-8.43%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
-0.42%-0.23%-6.56%-11.10%+0.41%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biogen Inc. stock logo
BIIB
Biogen
4.9689 of 5 stars
4.34.00.03.53.43.32.5
Cerner Co. stock logo
CERN
Cerner
2.8682 of 5 stars
0.00.02.53.91.11.72.5
ResMed Inc. stock logo
RMD
ResMed
4.6409 of 5 stars
2.41.03.34.53.71.72.5
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
4.8515 of 5 stars
2.43.03.33.23.32.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.65
Moderate Buy$288.4630.23% Upside
Cerner Co. stock logo
CERN
Cerner
N/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$202.80-5.15% Downside
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
2.80
Moderate Buy$435.2019.50% Upside

Current Analyst Ratings

Latest CERN, BIIB, WST, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Biogen Inc. stock logo
BIIB
Biogen
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$339.00 ➝ $342.00
4/29/2024
Biogen Inc. stock logo
BIIB
Biogen
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $238.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$224.00 ➝ $236.00
4/25/2024
Biogen Inc. stock logo
BIIB
Biogen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$215.00 ➝ $200.00
4/25/2024
Biogen Inc. stock logo
BIIB
Biogen
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$213.00 ➝ $215.00
4/25/2024
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$325.00 ➝ $300.00
4/24/2024
Biogen Inc. stock logo
BIIB
Biogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$294.00
4/19/2024
Biogen Inc. stock logo
BIIB
Biogen
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$290.00 ➝ $270.00
(Data available from 5/11/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.84B3.28$18.32 per share12.09$104.49 per share2.12
Cerner Co. stock logo
CERN
Cerner
$5.76B4.84$5.37 per share17.69$12.56 per share7.56
ResMed Inc. stock logo
RMD
ResMed
$4.22B7.44$7.70 per share27.77$31.52 per share6.78
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$2.93B9.06$10.14 per share35.92$36.80 per share9.90

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.16B$8.0127.6512.612.2612.07%14.83%8.19%7/23/2024 (Estimated)
Cerner Co. stock logo
CERN
Cerner
$555.60M$1.9947.7027.432.3710.15%22.86%11.75%N/A
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.5132.8424.922.6820.91%24.43%15.70%8/1/2024 (Estimated)
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$593.40M$7.5848.0539.806.4419.42%20.57%15.47%7/25/2024 (Estimated)

Latest CERN, BIIB, WST, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024Q3 24
ResMed Inc. stock logo
RMD
ResMed
$1.91$2.13+$0.22$2.22$1.17 billion$1.20 billion    
4/25/2024Q1 2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.29$1.56+$0.27$1.57$670.62 million$695.40 million    
4/24/2024Q1 2024
Biogen Inc. stock logo
BIIB
Biogen
$3.45$3.67+$0.22$4.64$2.31 billion$2.29 billion      
2/15/202412/31/2023
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.78$1.83+$0.05$1.83$740.43 million$732.00 million      
2/13/2024Q4 23
Biogen Inc. stock logo
BIIB
Biogen
$3.18$2.95-$0.23$4.19$2.47 billion$2.39 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Cerner Co. stock logo
CERN
Cerner
$1.081.14%N/A54.27%N/A
ResMed Inc. stock logo
RMD
ResMed
$1.920.90%+5.66%29.49%12 Years
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$0.800.22%+5.81%10.55%31 Years

Latest CERN, BIIB, WST, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Quarterly$0.200.22%7/31/20247/31/20248/7/2024
4/25/2024
ResMed Inc. stock logo
RMD
ResMed
Quarterly$0.480.88%5/8/20245/9/20246/13/2024
2/20/2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Quarterly$0.200.23%4/23/20244/24/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.41
2.10
1.32
Cerner Co. stock logo
CERN
Cerner
0.41
1.79
1.77
ResMed Inc. stock logo
RMD
ResMed
0.22
3.04
1.97
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.03
2.61
1.95

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Cerner Co. stock logo
CERN
Cerner
82.23%
ResMed Inc. stock logo
RMD
ResMed
54.98%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
93.90%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.60%
Cerner Co. stock logo
CERN
Cerner
0.12%
ResMed Inc. stock logo
RMD
ResMed
1.21%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,570145.60 million144.72 millionOptionable
Cerner Co. stock logo
CERN
Cerner
25,150294.10 million293.75 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140146.91 million145.13 millionOptionable
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
10,60072.84 million72.46 millionOptionable

CERN, BIIB, WST, and RMD Headlines

SourceHeadline
Versor Investments LP Buys Shares of 4,070 West Pharmaceutical Services, Inc. (NYSE:WST)Versor Investments LP Buys Shares of 4,070 West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - May 11 at 2:48 PM
West Pharmaceutical: Pick And Shovels Of The Injectable Drug IndustryWest Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
seekingalpha.com - May 11 at 10:37 AM
Eric Mark Green Sells 66,000 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) StockEric Mark Green Sells 66,000 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) Stock
insidertrades.com - May 11 at 4:14 AM
Insider Selling: West Pharmaceutical Services, Inc. (NYSE:WST) CEO Sells 66,000 Shares of StockInsider Selling: West Pharmaceutical Services, Inc. (NYSE:WST) CEO Sells 66,000 Shares of Stock
marketbeat.com - May 9 at 4:53 PM
National Bank of Canada FI Cuts Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)National Bank of Canada FI Cuts Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - May 8 at 8:55 AM
Natixis Advisors L.P. Decreases Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)Natixis Advisors L.P. Decreases Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - May 7 at 6:54 AM
West Pharmaceutical Services to Present at Bank of America Securities Healthcare ConferenceWest Pharmaceutical Services to Present at Bank of America Securities Healthcare Conference
msn.com - May 6 at 3:37 AM
Swiss National Bank Trims Position in West Pharmaceutical Services, Inc. (NYSE:WST)Swiss National Bank Trims Position in West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - May 5 at 8:35 AM
TCG Advisory Services LLC Buys Shares of 2,225 West Pharmaceutical Services, Inc. (NYSE:WST)TCG Advisory Services LLC Buys Shares of 2,225 West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - May 4 at 3:34 PM
Truist Financial Corp Cuts Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)Truist Financial Corp Cuts Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - May 2 at 5:40 AM
West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Rating of "Moderate Buy" from BrokeragesWest Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Rating of "Moderate Buy" from Brokerages
americanbankingnews.com - May 1 at 3:12 AM
West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2024 Earnings Call TranscriptWest Pharmaceutical Services, Inc. (NYSE:WST) Q1 2024 Earnings Call Transcript
finance.yahoo.com - April 30 at 9:32 AM
West Pharmaceutical Services, Inc. (NYSE:WST) Shares Sold by Russell Investments Group Ltd.West Pharmaceutical Services, Inc. (NYSE:WST) Shares Sold by Russell Investments Group Ltd.
marketbeat.com - April 30 at 7:20 AM
West to Participate in Upcoming Investor ConferenceWest to Participate in Upcoming Investor Conference
prnewswire.com - April 30 at 6:00 AM
West Pharmaceutical Services Posts Q1 2024 Financial Results, Updates Full-Year GuidanceWest Pharmaceutical Services Posts Q1 2024 Financial Results, Updates Full-Year Guidance
msn.com - April 29 at 8:30 AM
Paradiem LLC Has $3.49 Million Stake in West Pharmaceutical Services, Inc. (NYSE:WST)Paradiem LLC Has $3.49 Million Stake in West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - April 28 at 1:50 PM
West Pharmaceutical Services, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsWest Pharmaceutical Services, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - April 28 at 12:07 PM
West Pharmaceutical Services, Inc. (WST) Q1 2024 Earnings Call TranscriptWest Pharmaceutical Services, Inc. (WST) Q1 2024 Earnings Call Transcript
seekingalpha.com - April 27 at 4:03 PM
Bank Julius Baer & Co. Ltd Zurich Purchases Shares of 8,207 West Pharmaceutical Services, Inc. (NYSE:WST)Bank Julius Baer & Co. Ltd Zurich Purchases Shares of 8,207 West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - April 27 at 8:31 AM
Stevens Capital Management LP Purchases New Stake in West Pharmaceutical Services, Inc. (NYSE:WST)Stevens Capital Management LP Purchases New Stake in West Pharmaceutical Services, Inc. (NYSE:WST)
marketbeat.com - April 26 at 5:57 PM
West Pharmaceutical Services: Strong Q1 Performance and Upbeat FY24 Outlook Bolster Buy RatingWest Pharmaceutical Services: Strong Q1 Performance and Upbeat FY24 Outlook Bolster Buy Rating
markets.businessinsider.com - April 26 at 2:59 PM
West Pharmaceutical Services (NYSE:WST) Releases Quarterly  Earnings Results, Beats Expectations By $0.27 EPSWest Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results, Beats Expectations By $0.27 EPS
marketbeat.com - April 26 at 11:48 AM
West Pharmaceutical Services First Quarter 2024 Earnings: Beats ExpectationsWest Pharmaceutical Services First Quarter 2024 Earnings: Beats Expectations
finance.yahoo.com - April 26 at 9:58 AM
West Pharmaceutical Services, Inc. Declares Quarterly Dividend of $0.20 (NYSE:WST)West Pharmaceutical Services, Inc. Declares Quarterly Dividend of $0.20 (NYSE:WST)
marketbeat.com - April 26 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Biogen logo

Biogen

NASDAQ:BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Cerner logo

Cerner

NASDAQ:CERN
Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
West Pharmaceutical Services logo

West Pharmaceutical Services

NYSE:WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.